Immunotherapeutic potential of blinatumomab-secreting γ9δ2 T Cells

Previous studies have explored the use of engineered blinatumomab-secreting autologous αβ T cells for CD19-targeted cancer therapy. To create a more flexible allogeneic delivery system, we utilized γ9δ2 T cells rather than αβ T cells in a similar application. First, we showed that γ9δ2 T cells could...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Shang-Ju, Lin, Chien-Ting, Liao, Cheng Hao, Lin, Chun-Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024132/
https://www.ncbi.nlm.nih.gov/pubmed/36917873
http://dx.doi.org/10.1016/j.tranon.2023.101650

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024132/
https://www.ncbi.nlm.nih.gov/pubmed/36917873
http://dx.doi.org/10.1016/j.tranon.2023.101650

Ejemplares similares